Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus

被引：2
|
作者：
Urbanska, Aleksandra M. [1 ]
Ponnazhagan, Selvarangan [2 ]
Mozafari, Masoud [3 ,4 ,5 ]
机构：
[1] Columbia Univ, Dept Med, Med Ctr, Div Digest & Liver Dis, New York, NY USA
[2] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[3] MERC, Nanotechnol & Adv Mat Dept, Bioengn Res Grp, Tehran, Iran
[4] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran
[5] Iran Univ Med Sci, Fac Adv Technol Med, Dept Tissue Engn & Regenerat Med, Tehran, Iran
来源：
CANCER RESEARCH | 2018年 / 78卷 / 14期
关键词：
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; GASTROESOPHAGEAL-REFLUX DISEASE; ADENOCARCINOMA CELL-LINE; REDUCED RISK; RADIOFREQUENCY ABLATION; NEOPLASTIC PROGRESSION; ENDOSCOPIC RESECTION; HELICOBACTER-PYLORI; COST-EFFECTIVENESS;
D O I：
10.1158/0008-5472.CAN-18-0206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite esophageal adenocarcinoma (EAC) being the most widespread among gastrointestinal cancers, with an 11-fold increase in the risk of cancer for patients with Barrett esophagus (BE), its prognosis is still poor. There is a critical need to better perceive the biology of cancer progression and identification of specific targets that are the hallmark of BE's progression. This review explores the established animal models of BE, including genetic, surgical and nonsurgical approaches, potential chemoprevention targets, and the reasoning behind their applications to prevent Barrett-related EAC. The key methodological features in the design feasibility of relevant studies are also discussed. (C) 2018 AACR.
引用
收藏
页码：3747 / 3754
页数：8
相关论文
共 50 条
  • [1] Chemoprevention in barrett's esophagus
    Ilyas S.
    Demars C.J.
    Buttar N.S.
    Journal of Gastrointestinal Cancer, 2007, 38 (1) : 1 - 9
  • [2] Dysplasia in Barrett esophagus - Implications for chemoprevention
    Lao, CD
    Simmons, M
    Syngal, S
    Bresalier, RS
    Fortlage, L
    Normolle, D
    Griffith, KA
    Appelman, HD
    Brenner, DE
    CANCER, 2004, 100 (08) : 1622 - 1627
  • [3] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [4] The role of chemoprevention in Barrett esophagus and esophageal adenocarcinoma
    Wani, Sachin
    Sharma, Prateek
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (06) : S135 - S140
  • [5] Chemoprevention in Barrett's Esophagus Current Status
    Zeb, Muhammad H.
    Baruah, Anushka
    Kossak, Sarah K.
    Buttar, Navtej S.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2015, 44 (02) : 391 - +
  • [6] Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma
    Bresalier, Robert S.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (08) : 2155 - 2162
  • [7] Patient preferences for chemoprevention in Barrett's esophagus
    Hur, Chin
    Broughton, Darcy E.
    Ozanne, Elissa
    Nishioka, Norman S.
    Gazelle, G. Scott
    GASTROENTEROLOGY, 2007, 132 (04) : A255 - A255
  • [8] Chemoprevention and Barrett's Esophagus: Decisions, Decisions
    Falk, Gary W.
    Jankowski, Janusz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (10): : 2443 - 2445
  • [9] INNOVATIVE TRANSLATIONAL MODELS TO STUDY HUMAN SYNOVIAL PATHOLOGY: TARGET VALIDATION AND PRECLINICAL IMAGING
    Di Ceglie, I.
    Broeren, M.
    Waterborg, C.
    Dorst, D.
    Thurlings, R.
    Laverman, P.
    van de Loo, F.
    van der Kraan, P.
    Koenders, M.
    van Lent, P.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S302 - S302
  • [10] INNOVATIVE TRANSLATIONAL MODELS TO STUDY HUMAN SYNOVIAL PATHOLOGY: TARGET VALIDATION AND PRECLINICAL IMAGING
    Di Ceglie, Irene
    Broeren, Mathijs
    ClaireWaterborg
    Dorst, Daphne
    Thurlings, R. M.
    Laverman, Peter
    de Loo, Fons van
    van der Kraan, Peter
    van Lent, Peter
    Koenders, Marije
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 110 - 111
12345